


THE UNIVERSITY OF CHICAGO

I hereby certify that this correspondence is being deposited with the United States Postal Service as Express Mail Post Office Addressee (Mail Label EL924390251US) in an envelope addressed to: U.S. Patent and Trademark Office, PO Box 2327, Arlington, VA 22202 on December 3, 2001


Edward A. Meilman
Registration No.: 24,735
OSTROLENK, FABER, GERB & SOFFEN, LLP
1180 Avenue of the Americas
New York, New York 10036-8403
Telephone: (212) 382-0700

EAM:sam

APPENDIX B
VERSION WITH MARKINGS TO SHOW CHANGES MADE
37 C.F.R. § 1.121(b)(iii) AND (c)(ii)

CLAIMS:

(Amended) 3. The pharmaceutical composition according to [any of Claims] claim 1 [to 2], wherein the stabilizing agent is saccharose alone.

(Amended) 4. The pharmaceutical composition according to [any of claims] claim 1 [to 3], containing 3 or 10 mg/vial of hGRF.

(Amended) 5. The pharmaceutical composition according to [any of Claims] claim 1 [to 4] comprising 3 or 10 mg/vial of hGRF and 20.52 or 68.4 mg/vial of saccharose.

(Amended) 6. The pharmaceutical composition according to [any of Claims] claim 1 [to 5] further comprising buffering agents.

(Amended) 7. A process for preparing a pharmaceutical composition according to [any of Claims] claim 1 [to 6], comprising the preparation of an aqueous solution of the components, the distribution within containers and the lyophilization in the containers.

(Amended) 8. Forms of presentation of said pharmaceutical composition comprising the solid mixture according to [any of Claims] claim 1 [to 6], hermetically closed in a sterile condition within a container suited for storage before use and for reconstitution of the mixture into a solvent or into a solution for injectables.

(Amended) 9. A solution comprising the solid mixture according to [any of Claims] claim 1 [to 6], reconstituted in a solvent or a solution for injectables.